Mis-expression of DUX4 protein is thus believed to underlie FSHD pathogenesis and DUX4 inhibition is currently the dominant approach to FSHD therapy (Tawil, 2020; Le Gall et al., 2020). Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.